Ocular Therapeutix公司 OCUL 深 沪
已收盘 05-15 16:00:00 美东时间
9.16
-0.340
-3.58%
华盛通- 最 高9.36
- 今 开9.29
- 成交量 237.37万股
- 最 低 9.04
- 昨 收 9.50
- 总市值 20.06亿
- 52周最高 16.44
- 市盈率 静 --
- 换手率 1.08%
- 52周最低 6.2301
- 委 比 -1.44%
- 总股本 2.19亿
- 历史最高 44.19
- 量 比 0.79
- 振 幅 3.37%
- 历史最低 1.995
- 每 手 1
- 风险率 1.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
RBC Capital Reiterates Outperform on Ocular Therapeutix, Maintains $30 Price Target
RBC Capital analyst Lisa Walter reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and maintains $30 price target.
05-06 23:49
Ocular Therapeutix shares are trading lower after the company reported worse-than-expected Q1 financial results.
Ocular Therapeutix shares are trading lower after the company reported worse-th...
05-06 02:13
财报速睇 | Ocular Therapeutix公司 2026财年Q1营收0.11亿美元，同比增长0.8%；归母净利润亏损0.89亿美元，同比亏损扩大38.3%
华盛资讯5月5日讯，Ocular Therapeutix公司公布2026财年Q1业绩，公司Q1营收0.11亿美元，同比增长0.8%，归母净利润亏损0.89亿美元，同比亏损扩大38.3%。
05-05 19:46
Earnings Scheduled For May 5, 2026
Companies Reporting Before The Bell • Repligen (NASDAQ:RGEN) is projected to re...
05-05 19:12
美股大行评级 | 大摩上调哔哩哔哩目标价从25美元升至31美元；大砍近50%！汇丰下调耐克目标价从90美元降至48美元
今日重点评级关注：HC Wainwright & Co.：维持Solaris Resources"买入"评级，目标价从16美元升至18美元；Leerink Partners：维持Spyre Therapeutics"跑赢大市"评级，目标价从49美元升至106美元
04-14 10:44
Ocular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study
Ocular Therapeutix shares up on positive data for wet AMD treatment. Company focusing on retinal diseases and on track for FDA submission.
04-14 01:31
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $21 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $21 price target.
04-14 00:59
Ocular Therapeutix Reports One-Year Results For Eye Disease Treatment
Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular"))), an integrated biopharmaceutical company committed to redefining the retina experience, today announced additional positive Week 52 data from the SOL-1 Phase 3
04-13 19:08
Ocular Therapeutix to present additional SOL-1 Phase 3 AXPAXLI data at April conferences
Ocular Therapeutix to present additional SOL-1 Phase 3 AXPAXLI data at April conferences Ocular Therapeutix will present additional SOL-1 Phase 3 superiority trial data and analyses for AXPAXLI (OTX-TKI) in wet age-related macular degeneration at Vit-Buckle Society annual meeting on April 9-11, 2026
04-01 19:07
